Dear EC-Vaccines team,

Please find attached the confidential pre-read which can be distributed to the group of Member State experts ahead of our presentation on Friday. We plan to present a subset of the slides on Friday in 30 minutes and leave 30 minutes for an open Q&A session on the presented and pre-read materials.

Best regards,

From: EC-VACCINES@ec.europa.eu; EC-VACCINES@ec.europa.eu

Dear [Name],

Thank you for your message. Otherwise, please kindly confirm if the slot on [Date] could be feasible.

Best regards,

EC Vaccines Team
Dear EC-Vaccines Team,

Thank you for your email. We understand the strictures of the tender procedure.

If you believe that may inform the need to change the date for the presentation, and potentially keep it on the as planned, let me know. In the meantime, I will reach out to my colleagues about as suggested, and respond by COB tomorrow.

Best regards,
Thank you very much for this confirmation and the very good meeting this morning.

Please allow me to brief you on aspects of a forthcoming scientific presentation meeting.

We have indeed run such technical/scientific presentations to Member State experts of one hour but often the Q&A session overruns a little bit since the interest from the participants is so high.

A presentation of 30 minutes would be a good baseline to invite questions from the audience in the remaining half an hour.

Grateful for any pre-reads and the slides you intend to present if possible two days before the meeting so that we can distribute to participants in good time.

The profiles of the participants range from to .

I trust this helps and is timely.

With kindest regards,
Dear dear EU team

We would like to confirm that we would be pleased to present on the technical/scientific aspects of the program to the Member States as proposed below. We understand it would be from 14:30 to 15:30.

Please let us know of any logistical considerations. I suppose that a good format would be to send a preread at least 1 day before (building on the document we shared recently), select a subset of slides to present in 15-20 minutes and leave the rest of the time for a broad Q&A session – but we are happy to adapt to what has worked best in other settings.

We will share what we have at that time, understanding it is always a bit short of what could be presented a bit later with more data and more insights. But it will be already enough for a good discussion. After reading through the document we sent, let us know if there are specific additional topics that the experts might want to hear about.

When you have the information, could you also send us the list of the experts nominated by the member states?

Best regards
Dearest,

I understand, but I think it would be better to have you presenting the vaccine asap, as we had some other companies. You can somehow indicate that you will have fresher results. I really recommend you come to the Member States as soon as you can. I hope it is feasible for you.

Best regards,

s

---

Dear,

Thank you much for the proposition and the kind words. Yes we are interested to do so, and let me come back to you with potential dates. I understand that might be an option for you. We can definitely present this data I sent, but it would be great to get that and I want to make sure with the team when we have it and if needed propose a few days later if that
is what it means – without delaying more than useful for a good
discussion
Best regards

Dear

Many thanks for this, but I would like to give you the same opportunity
that other companies had to present in 60-90 minutes your vaccine to
the MS. We can arrange that for instance next Friday.

We believe in you, and it would be really good that tomorrow we get
My Colleagues are very helpful and I am sure
that together we will reach the balanced result we reached with other
companies. Such progress would really be important.

Kind regards,
S

European Commission
DG SANTE
SANTE.DG1 in charge of Directions B and C
Office Brussels/Belgium
Subject: [ccuurevaac.com]

Dear EU team

I know tomorrow we are speaking about a wonderful topic. But don't forget that it is vaccines that have the public health impact, not contracts.

So as we promised last time we spoke, we also wanted to provide you with a confidential project update in terms of

We also put more information about relevant results and our hypothesis is that (under reserve of full data coming through and appropriate analysis)

You can share this with your Member State technical and scientific colleagues under the same strict confidentiality conditions.

Best regards
Dear,

We felt it was indeed easier to start clean once we had discussed all the comments and changes we wanted to make. We are clearly intent on a productive discussion tomorrow on the topic, so we will aim to go back and redline your initial proposal, but very pragmatically won't be able to send it until probably late tonight. However, the ideas we will redline the document and wish to discuss are essentially the ones reflected in the document we sent, so in terms of preparing the discussion, you can go through these few pages. We look forward to our discussion tomorrow.

Best regards,

From: @ec.europa.eu
Sent: @curevac.com>
To: @ec.europa.eu; @ec.europa.eu; @ec.europa.eu; @ec.europa.eu; @pm.gouv.fr; @urp.gov.pl; @yahoo.com; @igf.finances.gouv.fr; com

Subject: RE:

Dear,

Thank you for your proposal as a reply to our clause. However, we have to express our gratitude and appreciation for your efforts. In our experience an
For no obvious benefit to either party. This is the more so as time is of the essence in our discussions.

Looking forward to a constructive discussion tomorrow.

Kind regards,

@curevac.com>

Dear,
I confirm that this coming Tuesday works on our side, 9:30-10:30 to discuss the issues. On our side, it will be (all in cc for the emails/invitations). Thank you for proposing to organize the webex.

We have carefully reviewed the document provided to us, and send you back our revised proposal.

We look forward to the discussion.

Best regards